Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.54 |
| ▸ | CCR5 | P51681 | 17/20 | 0.46 |
| ▸ | CCR7 | P32248 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339026 | 0.97 | CCR2 (0.55) | CCR2CCR5CCR7 | |
| SCHEMBL6345294 | 0.94 | CCR2 (0.52) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6350678 | 0.94 | CCR2 (0.56) | CCR2CCR5CCR7 | |
| SCHEMBL6342709 | 0.93 | CCR2 (0.51) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6341920 | 0.93 | CCR2 (0.51) | CCR2CCR5CCR7 | |
| SCHEMBL6344189 | 0.93 | CCR2 (0.51) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6342640 | 0.92 | CCR2 (0.50) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6344939 | 0.92 | CCR2 (0.52) | CCR2CCR5CCR7 | |
| SCHEMBL6341984 | 0.91 | CCR2 (0.49) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6350462 | 0.91 | CCR2 (0.49) | CCR2CCR5CCR7CCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936602-B1 | Benzazepine derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-30 | — | — | US | claimed |
| EP-1186604-A1 | BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-13 | — | — | EP | claimed |
| US-6936602-B1 | Benzazepine derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20030078189-A1 | Medicinal compositions for oral use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1236476-A1 | MEDICINAL COMPOSITIONS FOR ORAL USE | Takeda Chemical Industries, Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-1186604-A1 | BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078189-A1 | Medicinal compositions for oral use | CCR5, CXCR3, CCL5 | CCR2 23/4885CCR5 1/4885CCR7 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.